Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials
by
Barbui C, Furukawa TA, Cipriani A.
Department of Medicine and Public Health,
Section of Psychiatry and Clinical Psychology,
World Health Organization Collaborating Centre for Research and Training in Mental Health,
University of Verona, Verona, Italy.
corrado.barbui@univr.it
CMAJ. 2008 Jan 29;178(3):296-305.

ABSTRACT

BACKGROUND: Concern has been raised about the efficacy of antidepressant therapy for major depression in adults. We undertook a systematic review of published and unpublished clinical trial data to determine the effectiveness and acceptability of paroxetine. METHODS: We searched the Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register, the Cochrane Central Register of Controlled Trials, the GlaxoSmithKline Clinical Trial Register, MEDLINE and EMBASE up to December 2006. Published and unpublished randomized trials comparing paroxetine with placebo in adults with major depression were eligible for inclusion. We selected the proportion of patients who left a study early for any reason as the primary outcome measure because it represents a hard measure of treatment effectiveness and acceptability. RESULTS: We included in our review 29 published and 11 unpublished clinical trials, with a total of 3704 patients who received paroxetine and 2687 who received with placebo. There was no difference between paroxetine and placebo in terms of the proportion of patients who left the study early for any reason (random effect relative risk [RR] 0.99, 99% confidence interval [CI] 0.88-1.11). Paroxetine was more effective than placebo, with fewer patients who did not experience improvement in symptoms of at least 50% (random effect RR 0.83, 99% CI 0.77-0.90). Significantly more patients in the paroxetine group than in the placebo group left their respective studies because of side effects (random effect RR 1.77, 95% CI 1.44-2.18) or experienced suicidal tendencies (odds ratio 2.55, 95% CI 1.17-5.54). INTERPRETATION: Among adults with moderate to severe major depression in the clinical trials we reviewed, paroxetine was not superior to placebo in terms of overall treatment effectiveness and acceptability. These results were not biased by selective inclusion of published studies.

SSRIs
Anxiety
Serotonin
Paroxetine
Social phobia
Panic disorder
Paroxetine update
Paroxetine: structure
Paroxetine and suicide
Paroxetine v bupropion
Paroxetine v fluoxetine
Paroxetine in psychiatry
Paroxetine v maprotiline
SSRIs and panic disorder
Antidepressant metabolism
Paroxetine and noradrenaline
OCD: mice, marbles and paroxetine
Tianeptine (Stablon) v paroxetine (Paxil)
Paroxetine: controlled- v immediate-release
Paroxetine (Paxil): prescribing information (PDF)

Refs
and further reading

HOME
HedWeb
Nootropics
cocaine.wiki
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family